Protein Engineering, Vol. 16, No. 4, 311-317,
April 2003
© 2003 Oxford University Press
The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20
Institute of Chemistry, Academia Sinica, Taipei 11529, Taiwan 1 Present address: Department of Microbiology and Molecular Genetics, University of Texas Medical School, Houston, TX 77030-1501, USA
2 To whom correspondence should be addressed.E-mail: dkc{at}chem.sinica.edu.tw
A number of peptides and peptide analogs derived from the membrane proximal region of gp41 ectodomain are found to be effective inhibitors of human immunodeficiency virus type 1 (HIV-1)-mediated fusion events. One of them, T20 (aa 638–673), was found disordered and sparingly soluble in water, but became soluble upon mixing with selected, structured peptides from the amino terminal heptad repeat (HR1) region of gp41 using a simple and sensitive method of reduction in the scattering of T20 suspension. From the results on mapping the locus of interaction with T20 by employing partially overlapping peptides derived from HR1, it was concluded that the LLSGIV segment was a critical docking site for the C-terminal peptide of gp41 in its putative inhibitory action consistent with a previous fluorescence study. It was also found that peptides capable of solubilizing T20 dispersion have a high content of helix, as well as ß-strand, conformation in aqueous solution. Specificity of T20/HR1-derived peptide binding was ascertained by using a scrambled sequence of a T20-active peptide and a plateau in scattering reduction of T20 suspension with variation in the concentration of a T20-active HR1 peptide. Implications on the mechanism of T20 inhibition and the sequence of folding of the gp41 core structure are discussed.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Eggink, J. P. M. Langedijk, A. M. J. J. Bonvin, Y. Deng, M. Lu, B. Berkhout, and R. W. Sanders Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion Inhibitors J. Biol. Chem., September 25, 2009; 284(39): 26941 - 26950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pan, L. Cai, H. Lu, Z. Qi, and S. Jiang Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains J. Virol., August 15, 2009; 83(16): 7862 - 7872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Hermann, L. Egerer, F. Brauer, C. Gerum, H. Schwalbe, U. Dietrich, and D. von Laer Mutations in gp120 Contribute to the Resistance of Human Immunodeficiency Virus Type 1 to Membrane-Anchored C-Peptide maC46 J. Virol., May 15, 2009; 83(10): 4844 - 4853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Perdomo, M. Levi, M. Sallberg, and A. Vahlne From the Cover: Neutralization of HIV-1 by redirection of natural antibodies PNAS, August 26, 2008; 105(34): 12515 - 12520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. He, J. Cheng, J. Li, Z. Qi, H. Lu, M. Dong, S. Jiang, and Q. Dai Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors J. Virol., July 1, 2008; 82(13): 6349 - 6358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Eggink, C. E. Baldwin, Y. Deng, J. P. M. Langedijk, M. Lu, R. W. Sanders, and B. Berkhout Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants J. Virol., July 1, 2008; 82(13): 6678 - 6688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, W. Jing, B. Cheung, H. Lu, J. Sun, X. Yan, J. Niu, J. Farmar, S. Wu, and S. Jiang HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains: RELATION TO MECHANISMS OF ACTION OF ANTI-HIV PEPTIDES J. Biol. Chem., March 30, 2007; 282(13): 9612 - 9620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lohrengel, F. Hermann, I. Hagmann, H. Oberwinkler, L. Scrivano, C. Hoffmann, D. von Laer, and M. T. Dittmar Determinants of Human Immunodeficiency Virus Type 1 Resistance to Membrane-Anchored gp41-Derived Peptides J. Virol., August 15, 2005; 79(16): 10237 - 10246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kinomoto, M. Yokoyama, H. Sato, A. Kojima, T. Kurata, K. Ikuta, T. Sata, and K. Tokunaga Amino Acid 36 in the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Controls Fusogenic Activity: Implications for the Molecular Mechanism of Viral Escape from a Fusion Inhibitor J. Virol., May 15, 2005; 79(10): 5996 - 6004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Desmezieres, N. Gupta, R. Vassell, Y. He, K. Peden, L. Sirota, Z. Yang, P. Wingfield, and C. D. Weiss Human Immunodeficiency Virus (HIV) gp41 Escape Mutants: Cross-Resistance to Peptide Inhibitors of HIV Fusion and Altered Receptor Activation of gp120 J. Virol., April 15, 2005; 79(8): 4774 - 4781. [Abstract] [Full Text] [PDF]
|
|